NCT01190748View on ClinicalTrials.gov

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Healthy
Interventions
DRUG

Galantamine 4 mg Tablet, single dose

A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions

DRUG

Reminyl 4 mg Tablet, single dose

B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions

Trial Locations (1)

G 1 V 2K8

SFBC Anapharm, Sainte-Foy

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT01190748 - Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions | Biotech Hunter | Biotech Hunter